

## APC anti-mouse CD115 (CSF-1R) Antibody

<b>Catalog# / Size</b>	135509 / 25 µg 135510 / 100 µg
<b>Clone</b>	AFS98
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	CSF-1R, M-CSFR, c-fms
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CSF-1R, also known as CD115 and M-CSFR, is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family. This c-fms (Fms proto-oncogene) gene product's natural ligands include M-CSF and IL-34. Structural studies of CD115 have described an Ig-like extracellular domain, a transmembrane domain, an intracellular juxtamembrane domain, a split tyrosine kinase domain, and a C-terminal tail receptor. Receptor activation induces homodimerization in addition to phosphorylation and ubiquitination of intracellular residues. CD115 directly influences tissue macrophage and osteoclast differentiation and proliferation. It is expressed on monocytes/macrophages, peritoneal exudate cells, plasmacytoid and conventional dendritic cells, and osteoclasts.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: blocking of ligand binding <sup>1</sup> . The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays.  It has been reported that CD115 can be rapidly internalized, especially when samples are exposed to room temperature. Approximate 33% decrease in CD115 expression has been observed between 0 and 4 hours after sample collection, while overnight incubation of the cells results in complete CD115 downregulation. Pre-treatment with EDTA and low temperatures (2 to 8°C) helps in maintaining surface expression of CD115 <sup>4</sup> .
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Sudo T, <i>et al.</i> 1995. <i>Oncogene</i> 11:2469.</li> <li>2. Murayama T, <i>et al.</i> 1999. <i>Circulation</i> 99:1740.</li> <li>3. Jaeger BN, <i>et al.</i> 2012. <i>J. Exp. Med.</i> 209:565. <a href="#">PubMed</a></li> <li>4. Breslin WL, <i>et al.</i> 2013. <i>J Immunol Methods.</i> 390(1-2):1 <a href="#">PubMed</a></li> <li>5. Dong L, <i>et al.</i> 2016. <i>Nature.</i> 539:304–308. <a href="#">PubMed</a></li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

### Product Citations

1. Kim JS, *et al.* 2020. *Immunity*. 54(1):176-190.e7. [PubMed](#)
2. Andrés-Blasco I, *et al.* 2015. *J Endocrinol*. 227: 179 - 191. [PubMed](#)
3. Hu S, *et al.* 2018. *Front Immunol*. 9:01. [PubMed](#)
4. Hickey A, *et al.* 2021. *Front Microbiol*. 12:653587. [PubMed](#)
5. Accarias S, *et al.* 2020. *J Cell Sci*. 133:. [PubMed](#)
6. Mason HD, *et al.* 2021. *JCI Insight*. 6:e149229. [PubMed](#)
7. Kobori T, *et al.* 2018. *Front Immunol*. 9:334. [PubMed](#)
8. Fujii Y, *et al.* 2022. *JBMR Plus*. 6:e10562. [PubMed](#)
9. Tilstam PV, *et al.* 2021. *J Clin Invest*. 131:. [PubMed](#)
10. Almutairi F, *et al.* 2021. *Front Immunol*. 12:772288. [PubMed](#)
11. Hong H, *et al.* 2013. *Biochem Biophys Res Commun*. 440:545. [PubMed](#)
12. Svahn S, *et al.* 2015. *Infect Immun* . 83:514. [PubMed](#)
13. Izquierdo-Useros N, *et al.* 2014. *J Immunol* . 192:4852-4858. [PubMed](#)
14. He W *et al.* 2018. *Immunity*. 49(6):1175-1190 . [PubMed](#)
15. Pedragosa J, *et al.* 2020. *J Cereb Blood Flow Metab*. 40:S98. [PubMed](#)
16. Shami A, *et al.* 2015. *Sci Rep*. 5: 13904. [PubMed](#)
17. Saulnier N, *et al.* 2013. *PLoS One*. 7:30788. [PubMed](#)
18. Galvani S, *et al.* 2015. *Sci Signal*. 8: ra79. [PubMed](#)
19. Wang J, *et al.* 2021. *Nat Commun*. 12:6198. [PubMed](#)
20. Herrero-Cervera A, *et al.* 2019. *Diabetologia*. 62:2143. [PubMed](#)
21. Sauter K, *et al.* 2014. *J Leukoc Biol*. 96:265. [PubMed](#)
22. Kubota S, *et al.* 2019. *Nat Commun*. 10:1653. [PubMed](#)
23. Svahn S, *et al.* 2016. *Infect Immun* . 84: 1205-1213. [PubMed](#)
24. Wang X, *et al.* 2016. *J Immunol*. 197(12):4750-4761. [PubMed](#)
25. Keerthivasan S, *et al.* 2021. *Immunity*. 54(7):1511-1526.e8. [PubMed](#)
26. Ledo JH, *et al.* 2020. *PLoS One*. e0237773:15. [PubMed](#)
27. Huo M, *et al.* 2017. *FASEB J*. 10.1096/fj.201601030R. [PubMed](#)
28. Kitamura K, *et al.* 2019. *Int J Cardiol Heart Vasc*. 23:100344. [PubMed](#)
29. Clemente-Casares X, *et al.* 2017. *Immunity*. 47:974. [PubMed](#)
30. Baratin M, *et al.* 2017. *Immunity*. 47:349. [PubMed](#)
31. Reed-Geaghan EG, *et al.* 2020. *J Exp Med*. 217:00:00. [PubMed](#)
32. Asada S, *et al.* 2018. *Nat Commun*. 9:2733. [PubMed](#)
33. Theurich S *et al.* 2017. *Cell metabolism*. 26(1):171-184 . [PubMed](#)
34. Viaud M, *et al.* 2020. *Cell Reports*. 30(10):3397-3410. [PubMed](#)
35. Tähtinen S, *et al.* 2022. *Nat Immunol*. 23:532. [PubMed](#)
36. Kwok I, *et al.* 2020. *Immunity*. 53(2):303-318.e5. [PubMed](#)
37. Fransén Pettersson N, *et al.* 2018. *PLoS One*. 13:e0203228. [PubMed](#)
38. Han P, *et al.* 2020. *Sci Adv*. 6:eaaz1580. [PubMed](#)
39. Park SM *et al.* 2018. *Cell stem cell*. 24(1):153-165 . [PubMed](#)
40. O'Boyle C, *et al.* 2020. *Int J Stroke*. 0.746527778. [PubMed](#)
41. Zhang B, *et al.* 2021. *Front Neurol*. 607370:12. [PubMed](#)
42. Ledo JH, *et al.* 2020. *Mol Psychiatry*. . [PubMed](#)
43. Buschor S, *et al.* 2017. *PLoS Pathogens*. 13(6):e1006476. [PubMed](#)
44. Cleary MM, *et al.* 2021. *Mol Cancer Ther*. 20:906. [PubMed](#)

## RRID

AB\_2085222 (BioLegend Cat. No. 135509)  
 AB\_2085221 (BioLegend Cat. No. 135510)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, 145 kD
<b>Distribution</b>	Monocytes/macrophages, peritoneal exudate cells, plasmacytoid and conventional dendritic cells, osteoclasts
<b>Function</b>	Growth factor receptor, tyrosine kinase
<b>Ligand/Receptor</b>	Macrophage colony stimulating factor (M-CSF), IL-34
<b>Cell Type</b>	Dendritic cells, Macrophages, Monocytes, Osteoclasts
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules, Cytokine/Chemokine Receptors
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Sudo T, <i>et al.</i> 1995 <i>Oncogene</i> 11:2469.</li> <li>2. Murayama T, <i>et al.</i> 1999 <i>Circulation</i> 99:1740.</li> <li>3. Goswami S, <i>et al.</i> 2005 <i>Cancer Res</i>. 65:5278.</li> <li>4. Yu W, <i>et al.</i> 2008 <i>J. Leuko. Biol</i>. 84:852.</li> </ol>
<b>Gene ID</b>	<a href="#">12978</a>



## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Purified anti-mouse CD115 (CSF-1R), PE anti-mouse CD115 (CSF-1R), Biotin anti-mouse CD115 (CSF-1R), APC anti-mouse CD115 (CSF-1R), Alexa Fluor® 488 anti-mouse CD115 (CSF-1R), Brilliant Violet 421™ anti-mouse CD115 (CSF-1R), Brilliant Violet 605™ anti-mouse CD115 (CSF-1R), Brilliant Violet 711™ anti-mouse CD115 (CSF-1R), Alexa Fluor® 594 anti-mouse CD115 (CSF-1R), Purified anti-mouse CD115 (CSF-1R) (Maxpar® Ready), PE/Cyanine7 anti-mouse CD115 (CSF-1R), PerCP/Cyanine5.5 anti-mouse CD115 (CSF-1R), PE/Dazzle™ 594 anti-mouse CD115 (CSF-1R), Alexa Fluor® 647 anti-mouse CD115 (CSF-1R), APC/Cyanine7 anti-mouse CD115 (CSF-1R), TotalSeq™-A0105 anti-mouse CD115 (CSF-1R), APC/Fire™ 750 anti-mouse CD115 (CSF-1R), Ultra-LEAF™ Purified anti-mouse CD115 (CSF-1R), TotalSeq™-B0105 anti-mouse CD115 (CSF-1R), TotalSeq™-C0105 anti-mouse CD115 (CSF-1R)

## Product Data



Thioglycolate-elicited BALB/c mouse peritoneal macrophages stained with CD11b FITC and AFS98 APC (top) or rat IgG2a,k APC (bottom).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587